---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000104"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:26:10.937765+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte completes enrollment in Phase 2/3 vascular trauma trial; BLA filing planned for Q4 2023

## Summary
- Enrollment completed in V005 trial; 68 patients received HAV, 51 in primary efficacy analysis for extremity trauma.
- Top-line results expected in Q3 2023; BLA submission to FDA planned for Q4 2023.
- RMAT designation from FDA received in May 2023 increases chance of priority review.
- Ukraine humanitarian program treated 19 trauma patients; data will be included in BLA.
- HAV has >1,000 patient-years of experience across multiple indications.

## SEC filing metadata
- accession: 0001818382-23-000104
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/0001818382-23-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000104/huma-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000104
- JSON: https://secwatch.observer/filing/0001818382-23-000104.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.